Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 6/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14206285 | 0.90 | HDAC4 (0.69) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL12392880 | 0.90 | HDAC4 (0.69) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL12368077 | 0.90 | HDAC4 (0.69) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL29602298 | 0.89 | HDAC4 (0.59) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL29884582 | 0.85 | HDAC4 (0.60) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL29666555 | 0.84 | HDAC4 (0.57) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| Cyclolinopeptide A SCHEMBL31609181 | 0.83 | ABCB1 (0.54) | HDAC4 | |
| SCHEMBL29354935 | 0.83 | GRB2 (0.64) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL2019443 | 0.82 | HDAC4 (0.73) | HDAC4HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL173749 | 0.82 | HDAC4 (0.73) | HDAC4HDAC1HDAC3HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140050728-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CYCLOPHILIN D FOR THE TREATMENT AND PREVENTION OF OBESITY AND KIDNEY INDICATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2014-02-20 | — | — | US | claimed |
| WO-2012103520-A1 | METHODS AND COMPOSITIONS FOR MODULATING CYCLOPHILIN D | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-08-02 | — | — | WO | claimed |
| JP-3309356-B2 | — | — | 2002-07-29 | — | — | JP | claimed |
| EP-0511273-B1 | LIPOSOMES AS CONTRAST AGENTS FOR ULTRASONIC IMAGING | IMARX PHARMACEUTICAL CORP (US) | 1999-05-19 | — | — | EP | claimed |
| US-5466667-A | Prophylactic and therapeutic methods for treating edema with antamanides | TRUSTEES OF BOSTON UNIVERSITY (US) | 1995-11-14 | — | — | US | claimed |
| US-5352435-A | Ionophore containing liposomes for ultrasound imaging | CITIZENS BANK, N.A. | 1994-10-04 | — | — | US | claimed |
| US-5278143-A | Administering an antamanide compound | TRUSTEES OF BOSTON UNIVERSITY (US) | 1994-01-11 | — | — | US | claimed |
| EP-0511273-A4 | LIPOSOMES AS CONTRAST AGENTS FOR ULTRASONIC IMAGING | — | 1993-03-31 | — | — | EP | claimed |
| EP-0511273-A1 | LIPOSOMES AS CONTRAST AGENTS FOR ULTRASONIC IMAGING | IMARX PHARMACEUTICAL CORP. (US) | 1992-11-04 | — | — | EP | claimed |
| EP-0493498-A1 | MEDICAMENT COMPRISING ANTAMANIDE | Ferring AB (SE) | 1992-07-08 | — | — | EP | claimed |
| US-5088499-A | Medical diagnosis | CITIZENS BANK, N.A. | 1992-02-18 | — | — | US | claimed |
| WO-1991009629-A1 | LIPOSOMES AS CONTRAST AGENTS FOR ULTRASONIC IMAGING | UNGER EVAN C (US) | 1991-07-11 | — | — | WO | claimed |
| WO-1991004269-A1 | MEDICAMENT COMPRISING ANTAMANIDE | FERRING AB (SE) | 1991-04-04 | — | — | WO | claimed |
| US-12576158-B2 | Antibody drug conjugates with cleavable linkers | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-03-17 | — | — | US | disclosed |
| US-20260000780-A1 | B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-01-01 | — | — | US | disclosed |
| EP-4611897-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | Heidelberg Pharma Research GmbH (DE) | 2025-09-10 | — | — | EP | disclosed |
| EP-0365656-A1 | PROPHYLACTIC AND THERAPEUTIC METHODS FOR TREATING EDEMA WITH PHALLOTOXINS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1990-05-02 | — | — | EP | disclosed |
| WO-1989010136-A1 | PROPHYLACTIC AND THERAPEUTIC METHODS FOR TREATING EDEMA WITH PHALLOTOXINS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1989-11-02 | — | — | WO | disclosed |
| US-4214968-A | Ion-selective electrode | EASTMAN KODAK COMPANY (US) | 1980-07-29 | — | — | US | disclosed |
| US-4122090-A | Cyclic esters of 3,4-dihydroxy-thiophene-1,1-dioxide compounds and 3,4-dihydroxy-cyclopentadienone compounds | BASF AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050728-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CYCLOPHILIN D FOR THE TREATMENT AND PREVENTION OF OBESITY AND KIDNEY INDICATIONS | PPIG, FKBP1B, PPIH | HDAC4 3004/4885HDAC1 1697/4885HDAC3 1981/4885 |
| US-12576158-B2 | Antibody drug conjugates with cleavable linkers | PTMS, C3AR1, ANPEP | HDAC4 2174/4885HDAC1 2772/4885HDAC3 888/4885 |
| US-20260000780-A1 | B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES | SIGLEC7, CD2, TNFSF10 | HDAC4 4528/4885HDAC1 4877/4885HDAC3 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.